Oncology Unscripted With John Marshall cover art

Oncology Unscripted With John Marshall

Oncology Unscripted With John Marshall

By: John Marshall
Listen for free

About this listen

 Oncology Unscripted with John Marshall, MD brings you a unique take on the latest oncology news including business news, gossip, science, and a special in-depth segment relevant to clinical practice. Language Learning
Episodes
  • Oncology Unscripted With John Marshall: Episode 28: Are We Watching a Global Evolution in Cancer Care Leadership?

    Oncology Unscripted With John Marshall: Episode 28: Are We Watching a Global Evolution in Cancer Care Leadership?
    Mar 25 2026

    MedBuzz:
    After a trip to the Galapagos, Dr John Marshall reflects on evolution in nature, cancer, and medicine. From Darwin’s observations to the rise of AI and precision oncology, he explores how rapidly cancer adapts, how technology is reshaping care, and why the future of medicine must still preserve the human touch.

    Main Topic:
    In this episode of Oncology Unscripted, Dr John Marshall reflects on a practice-changing cholangiocarcinoma study from China and what it reveals about the rapid evolution of cancer research worldwide. As novel therapies transform care and China expands its investment in science while the US devests, he asks whether we can keep pace and the impacts of the global evolution of in oncology.

    Interview:
    Watch now as Dr John Marshall sits down with Dr Louis Weiner, director of Georgetown University’s Lombardi Cancer Center, for a candid conversation about leadership, scientific change, and the future of oncology. Reflecting on innovation, institutional transition, and the pressures reshaping cancer research, they explore what it means to evolve as a leader and honoring the work and the people.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    30 mins
  • Oncology Unscripted With John Marshall: Episode 27: Groundhog Day, The Ice Palace, and $25 Trillion Cancer Costs

    Oncology Unscripted With John Marshall: Episode 27: Groundhog Day, The Ice Palace, and $25 Trillion Cancer Costs
    Feb 23 2026
    MedBuzz: Watch now as Dr Marshall discusses the growing instability at the FDA, including job cuts, leadership turnover, and structural reorganization. Main Topic: This episode of Oncology Unscripted explores the projected $25 trillion global cost of cancer care, rising cancer incidence, and declining mortality, all set against political and funding uncertainty in frozen Washington, DC. Interview: In this episode of Oncology Unscripted, John Marshall, MD, sits down with Richard Pazdur, MD, former director of the FDA’s Oncology Center of Excellence, for a candid discussion about his transition to and from the FDA, reflecting on what’s been built and what is at risk of being lost. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    33 mins
  • Oncology Unscripted With John Marshall: Episode 26: Microbes, Mutagens, and Mortality: CRC in a Younger Generation

    Oncology Unscripted With John Marshall: Episode 26: Microbes, Mutagens, and Mortality: CRC in a Younger Generation
    Jan 28 2026
    Oncology Unscripted at ASCO GI: People, Pipelines, and PrecisionJohn Marshall, MD:Hello, everybody, from San Francisco, California. My name is Dr. John Marshall, and you are on—maybe unwisely—Oncology Unscripted. But thanks for joining me. I love this meeting, but let's first talk about the news of 2026.Top of the line is: we're out to get new countries. Now, I'm sort of running for mayor of Havana. I don't know if it's important that I, in fact, speak Spanish—because I don't. I speak a little bit of French. My Spanish is terrible. But maybe it won't matter, because I am who I am, and they're looking for just my kind of person to go be mayor of Havana. So, if you see that and you get a chance to vote, vote me in. I love the whole country of Cuba—it's beautiful.Second, in today's newspaper—I couldn't believe it—this guy named Dr. Oz, you know him, he's an actual cardiologist, believe it or not. Then he became the talk show host. And then, for some reason, he's the head of CMS at this point—one of the head overseers of healthcare here in the country. And he said his position was that alcohol is good. This couldn’t have made me happier. This couldn’t have been a better holiday present, because I'm a big alcohol fan myself, and now I can feel less guilty about it. His rationale is that if you drink more, you'll be with people more, you'll be more relaxed, and the camaraderie will pay off in terms of lessening your anxiety and stress—and the world will be a happier place.So, don’t be smart. We don't want people in our country to be intelligent or educated. Drink more. Be less educated. You'll be happier in the long run. That's the official position of our government today.Probably the most important new news from a healthcare perspective is that the House approved an extension on the Affordable Care Act. This has been an incredible threat and uncertainty for so many of our patients. The people who depend on that health insurance could never afford cancer care without it. Having the extension of the Affordable Care Act—for them—talk about lowering your stress. Maybe better than alcohol is actually being insured.I don’t know if you go to many meetings out there, but this one is called GI ASCO. It's always in San Francisco. It's always in this building that I'm standing in now. I have perfect attendance. I’ve been to every one since they started. You should get a special ribbon for that. I think there’s probably one down there for that.They are a little bit more environmentally conscious—no plastic covering to this. Just a piece of paper. Totally recyclable old name badge. Way to go, ASCO, on that.Do you go to meetings or don’t you? I come to this one for a very, very important reason. I come to this one for the people. It’s a small meeting. It’s just the GI gang, both from the industry side and the academic side. It’s a very heavy global presence that comes. I know almost everybody here, and there are only like 3,000 people here. There’s time to stop and say hello to almost everybody you know—give them a hug, share a little COVID, maybe flu, with each other—but then know that you are connected again. And this is something Zoom doesn’t do. This is something you can’t check on—somebody’s kids—over a meeting. But that’s one of the main reasons I come.I love these people. These are people that share in our values and our motivation to try and cure cancer. We all take care of the group of cancers—GI cancers—which are the most common, most fatal cancers on our planet. We are inspired to do this. We know it’s a steep climb, and we do it together. I’m so very pleased to be a part of this community, and it’s the main reason I come.Main reason—people. Second reason—pipelines. There’s a lot of data out there, and there are a lot of companies here that finally have new products for GI cancers. We’ll talk a little bit about that in more specific detail, but if you just look at the number of groups that are here—the number of people who’ve got innovative, new approaches—whether it’s novel immunotherapy, targeted agents, combinations of those, targeted antibodies that are delivering toxic payloads—we’re seeing waterfall plots that we haven’t seen in decades.So, response rates, survivals, progression-free survivals that really compare favorably to our traditional chemotherapy approaches. We are on the cusp of a true revolution in the world of GI cancer.And, surprisingly, one more—led by the world of pancreatic cancer. So, let’s talk a little bit about precision in GI oncology. The biggest breakthroughs that we are seeing at this meeting have to do with RAS targeting.There are a bunch of RAS drugs out there now. There are some that are more out in front than others. There are some that are degraders that break down the RAS. There are some that block pan-RAS, so they hit a bunch of RAS targets. There are some that are very specific ...
    Show More Show Less
    34 mins
No reviews yet